Search

Your search keyword '"McWilliams, Robert R."' showing total 725 results
Start Over Author "McWilliams, Robert R."
725 results on '"McWilliams, Robert R."'

1. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Author

Hieken, Tina J., Nelson, Garth D., Flotte, Thomas J., Grewal, Eric P., Chen, Jun, McWilliams, Robert R., Kottschade, Lisa A., Yang, Lu, Domingo-Musibay, Evidio, Dronca, Roxana S., Yan, Yiyi, Markovic, Svetomir N., Dimou, Anastasios, Montane, Heather N., Erskine, Courtney L., Piltin, Mara A., Price, Daniel L., Khariwala, Samir S., Hui, Jane, Strand, Carrie A., Harrington, Susan M., Suman, Vera J., Dong, Haidong, and Block, Matthew S.

Published
2024
Full Text
View/download PDF

3. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

Author

Saberzadeh-Ardestani, Bahar, Jones, Jeremy C., McWilliams, Robert R., Tougeron, David, Halfdanarson, Thorvardur R., Guimbaud, Rosine, Hubbard, Joleen M., Flecchia, Clémence, Shi, Qian, Alouani, Emily, Sonbol, Mohamad B., Ticku, Jonathan, Jin, Zhaohui, Taieb, Julien, and Sinicrope, Frank A.

Published
2024
Full Text
View/download PDF

7. Prognostication of ß-catenin (CTNNB1) in patients with HCC treated with first line immunotherapy.

Author

Shah, Priyanshi M., primary, Peersen, Anina, additional, Jatoi, Aminah, additional, McWilliams, Robert R., additional, Jin, Zhaohui, additional, Torbenson, Michael S., additional, Halfdanarson, Thorvardur Ragnar, additional, Babiker, Hani M., additional, Conboy, Caitlin, additional, Kankeu Fonkoua, Lionel Aurelien, additional, Washburn, Leslie, additional, Roberts, Lewis R., additional, Gores, Gregory J., additional, Bekaii-Saab, Tanios S., additional, Borad, Mitesh J., additional, Ou, Fang-Shu, additional, and Tran, Nguyen H., additional

Published
2024
Full Text
View/download PDF

8. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Author

Desai, Aakash, primary, Xiao, Alexander H., additional, Choi, Daheui, additional, Toruner, Merih D., additional, Walden, Daniel, additional, Halfdanarson, Thorvardur R., additional, Alberts, Steven, additional, McWilliams, Robert R., additional, Mahipal, Amit, additional, Ahn, Daniel, additional, Babiker, Hani, additional, Stybayeva, Gulnaz, additional, Revzin, Alexander, additional, Kizilbash, Sani, additional, Adjei, Alex, additional, Bekaii-Saab, Tanios, additional, Mansfield, Aaron S., additional, Carr, Ryan M., additional, and Ma, Wen Wee, additional

Published
2024
Full Text
View/download PDF

9. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Author

Shroff, Rachna T, Hendifar, Andrew, McWilliams, Robert R, Geva, Ravit, Epelbaum, Ron, Rolfe, Lindsey, Goble, Sandra, Lin, Kevin K, Biankin, Andrew V, Giordano, Heidi, Vonderheide, Robert H, and Domchek, Susan M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Clinical Research, Orphan Drug, Rare Diseases, Pancreatic Cancer, Genetics, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Oncology and carcinogenesis
Abstract

Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germ-line; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic-not germline-mutation. Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.

Published
2018

13. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

Author

Kalogera, Eleftheria, primary, Nevala, Wendy K., additional, Finnes, Heidi D., additional, Suman, Vera J., additional, Schimke, Jill M., additional, Strand, Carrie A., additional, Kottschade, Lisa A., additional, Kudgus, Rachel A., additional, Buhrow, Sarah A., additional, Becher, Laura R., additional, Geng, Liyi, additional, Glaser, Gretchen E., additional, Grudem, Megan E., additional, Jatoi, Aminah, additional, Klampe, Carolyn M., additional, Kumar, Amanika, additional, Langstraat, Carrie L., additional, McWilliams, Robert R., additional, Wahner Hendrickson, Andrea E., additional, Weroha, S. John, additional, Yan, Yiyi, additional, Reid, Joel M., additional, Markovic, Svetomir N., additional, and Block, Matthew S., additional

Published
2024
Full Text
View/download PDF

14. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.

Author

Saberzadeh Ardestani, Bahar, primary, Jones, Jeremy Clifton, additional, McWilliams, Robert R., additional, Tougeron, David, additional, Halfdanarson, Thorvardur Ragnar, additional, Guimbaud, Rosine, additional, Hubbard, Joleen M., additional, Flecchia, Clémence, additional, Shi, Qian, additional, Alouani, Emily Linda, additional, Sonbol, Bassam Bassam, additional, Ticku, Jonathan, additional, Jin, Zhaohui, additional, Taieb, Julien, additional, and Sinicrope, Frank A., additional

Published
2024
Full Text
View/download PDF

16. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Author

Marabelle, Aurélien, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller, Wilson H, Jr, Italiano, Antoine, Kao, Steven, Piha-Paul, Sarina A, Delord, Jean-Pierre, McWilliams, Robert R, Fabrizio, David A, Aurora-Garg, Deepti, Xu, Lei, Jin, Fan, Norwood, Kevin, and Bang, Yung-Jue

Published
2020
Full Text
View/download PDF

17. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

Author

McCleary-Wheeler, Angela L., Carr, Ryan M., Palmer, Shanique R., Smyrk, Thomas C., Allred, Jacob B., Almada, Luciana L., Tolosa, Ezequiel J., Lamberti, Maria J., Marks, David L., Borad, Mitesh J., Molina, Julian R., Qi, Yingwei, Lingle, Wilma L., Grothey, Axel, Pitot, Henry C., Jatoi, Aminah, Northfelt, Donald W., Bryce, Alan H., McWilliams, Robert R., Okuno, Scott H., Haluska, Paul, Kim, George P., Colon-Otero, Gerardo, Lowe, Val J., Callstrom, Matthew R., Ma, Wen We, Bekaii-Saab, Tanios, Hung, Mien-Chie, Erlichman, Charles, and Fernandez-Zapico, Martin E.

Published
2020
Full Text
View/download PDF

18. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma

Author

Malikowski, Thomas, Lehrke, Heidi D., Henry, Michael R., Gleeson, Ferga C., Alberts, Steven R., Kendrick, Michael L., Lennon, Ryan J., McWilliams, Robert R., Takahashi, Naoki, Topazian, Mark D., Gara, Naveen, Abu Dayyeh, Barham K., Chandrasekhara, Vinay, Chari, Suresh T., Iyer, Prasad G., Rajan, Elizabeth, Storm, Andrew C., Wang, Kenneth K., and Levy, Michael J.

Published
2020
Full Text
View/download PDF

19. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study

Author

Kirkwood, John M, primary, Kottschade, Lisa A, additional, McWilliams, Robert R, additional, Khushalani, Nikhil I, additional, Jang, Sekwon, additional, Hallmeyer, Sigrun, additional, McDermott, David F, additional, Tawbi, Hussein, additional, Che, Min, additional, Lee, Cho-Han, additional, Ritchings, Corey, additional, Le, Trong Kim, additional, Park, Boas, additional, and Ramsey, Scott, additional

Published
2023
Full Text
View/download PDF

20. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

Author

Saberzadeh-Ardestani, Bahar, primary, Jones, Jeremy C., additional, McWilliams, Robert R., additional, Tougeron, David, additional, Halfdanarson, Thorvardur R., additional, Guimbaud, Rosine, additional, Hubbard, Joleen M., additional, Fleccia, Clémence, additional, Shi, Qian, additional, Alouani, Emily, additional, Sonbol, Bassam B., additional, Ticku, Jonathan, additional, Jin, Zhaohui, additional, Taieb, Julien, additional, and Sinicrope, Frank A., additional

Published
2023
Full Text
View/download PDF

21. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

Author

Smith, Katherine E. R., primary, Peng, Kah-Whye, additional, Pulido, Jose S., additional, Weisbrod, Adam J., additional, Strand, Carrie A., additional, Allred, Jacob B., additional, Newsom, Alysha N., additional, Zhang, Lianwen, additional, Packiriswamy, Nandakumar, additional, Kottke, Timothy, additional, Tonne, Jason M., additional, Moore, Madelyn, additional, Montane, Heather N., additional, Kottschade, Lisa A., additional, McWilliams, Robert R., additional, Dudek, Arkadiusz Z., additional, Yan, Yiyi, additional, Dimou, Anastasios, additional, Markovic, Svetomir N., additional, Federspiel, Mark J., additional, Vile, Richard G., additional, Dronca, Roxana S., additional, and Block, Matthew S., additional

Published
2023
Full Text
View/download PDF

22. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma

Author

Sener, Ugur, primary, Webb, Mason, additional, Breen, William G., additional, Neth, Bryan J., additional, Laack, Nadia N., additional, Routman, David, additional, Brown, Paul D., additional, Mahajan, Anita, additional, Frechette, Kelsey, additional, Dudek, Arkadiusz Z., additional, Markovic, Svetomir N., additional, Block, Matthew S., additional, McWilliams, Robert R., additional, Dimou, Anastasios, additional, Kottschade, Lisa A., additional, Montane, Heather N., additional, Kizilbash, Sani H., additional, and Campian, Jian L., additional

Published
2023
Full Text
View/download PDF

23. ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

Author

Alva-Ruiz, Roberto, Yohanathan, Lavanya, Yonkus, Jennifer A., Abdelrahman, Amro M., Gregory, Lindsey A., Halfdanarson, Thorvadur R., Mahipal, Amit, McWilliams, Robert R., Ma, Wen Wee, Hallemeier, Christopher L., Graham, Rondell P., Grotz, Travis E., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Kendrick, Michael L., and Truty, Mark J.

Published
2022
Full Text
View/download PDF

24. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Author

Johnson, Douglas B, Flaherty, Keith T, Weber, Jeffrey S, Infante, Jeffrey R, Kim, Kevin B, Kefford, Richard F, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H, McWilliams, Robert R, Sznol, Mario, Lawrence, Donald P, Gibney, Geoffrey T, Burris, Howard A, Falchook, Gerald S, Algazi, Alain, Lewis, Karl, Long, Georgina V, Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A, Daud, Adil, and Gonzalez, Rene

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Cancer, Development of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Disease-Free Survival, Female, Humans, Imidazoles, Male, Melanoma, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Mutation, Oximes, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment.Patients and methodsIn this open-label phase I/II study, we evaluated the pharmacology, safety, and efficacy of dabrafenib and trametinib. Here, we report patients treated with combination therapy after disease progression with BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-over at progression with dabrafenib monotherapy (part C; n = 45).ResultsIn parts B and C, confirmed objective response rates (ORR) were 15% (95% CI, 4% to 35%) and 13% (95% CI, 5% to 27%), respectively; an additional 50% and 44% experienced stable disease ≥ 8 weeks, respectively. In part C, median progression-free survival (PFS) was 3.6 months (95% CI, 2 to 4), and median overall survival was 11.8 months (95% CI, 8 to 25) from cross-over. Patients who previously received dabrafenib ≥ 6 months had superior outcomes with the combination compared with those treated < 6 months; median PFS was 3.9 (95% CI, 3 to 7) versus 1.8 months (95% CI, 2 to 4; hazard ratio, 0.49; P = .02), and ORR was 26% (95% CI, 10% to 48%) versus 0% (95% CI, 0% to 15%).ConclusionDabrafenib plus trametinib has modest clinical efficacy in patients with BRAF inhibitor-resistant melanoma. This regimen may be a therapeutic strategy for patients who previously benefited from BRAF inhibitor monotherapy ≥ 6 months but demonstrates minimal efficacy after rapid progression with BRAF inhibitor therapy.

Published
2014

27. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Author

Meric-Bernstam, Funda, Hurwitz, Herbert, Raghav, Kanwal Pratap Singh, McWilliams, Robert R, Fakih, Marwan, VanderWalde, Ari, Swanton, Charles, Kurzrock, Razelle, Burris, Howard, Sweeney, Christopher, Bose, Ron, Spigel, David R, Beattie, Mary S, Blotner, Steven, Stone, Alyssa, Schulze, Katja, Cuchelkar, Vaikunth, and Hainsworth, John

Published
2019
Full Text
View/download PDF

28. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.

Author

Sener, Ugur, Webb, Mason, Breen, William G., Neth, Bryan J., Laack, Nadia N., Routman, David, Brown, Paul D., Mahajan, Anita, Frechette, Kelsey, Dudek, Arkadiusz Z., Markovic, Svetomir N., Block, Matthew S., McWilliams, Robert R., Dimou, Anastasios, Kottschade, Lisa A., Montane, Heather N., Kizilbash, Sani H., and Campian, Jian L.

Subjects
PROTON therapy, MENINGEAL cancer, CANCER treatment, DISEASE progression, IMMUNE checkpoint inhibitors
Abstract

Introduction: Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic therapy to pCSI may improve outcomes. Methods: In this single-institution retrospective case series, we present the feasibility of treatment with pCSI (30Gy, 10 fractions) and an immune checkpoint inhibitor (ICI) in two sequential patients with LMD from melanoma. Results: The first patient developed LMD related to BRAF V600E-mutant melanoma after prior ICI and BRAF-targeted therapy. After pCSI with concurrent nivolumab, the addition of relatlimab, and BRAF-targeted therapy, he remained alive 7 months after LMD diagnosis despite central nervous system progression. The second patient developed LMD related to BRAF-wildtype melanoma after up-front ICI. He received pCSI with concurrent ipilimumab and nivolumab, then nivolumab maintenance. Though therapy was held for ICI hepatitis, the patient remained progression-free 5 months after LMD diagnosis. Conclusion: Adding an ICI to pCSI is feasible for patients with LMD and demonstrates a tolerable toxicity profile. While prospective evaluation is ultimately warranted, pCSI with ICI may confer survival benefits, even after prior ICI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection

Author

Zironda, Andrea, primary, Zhang, Chi, additional, Day, Courtney, additional, McWilliams, Robert R., additional, Starlinger, Patrick, additional, Warner, Susanne G., additional, Smoot, Rory L., additional, Cleary, Sean P., additional, Kendrick, Micheal L., additional, Truty, Mark J., additional, and Thiels, Cornelius A., additional

Published
2023
Full Text
View/download PDF

32. Preoperative Treatment of Locally Advanced Rectal Cancer

Author

Schrag, Deborah, primary, Shi, Qian, additional, Weiser, Martin R., additional, Gollub, Marc J., additional, Saltz, Leonard B., additional, Musher, Benjamin L., additional, Goldberg, Joel, additional, Al Baghdadi, Tareq, additional, Goodman, Karyn A., additional, McWilliams, Robert R., additional, Farma, Jeffrey M., additional, George, Thomas J., additional, Kennecke, Hagen F., additional, Shergill, Ardaman, additional, Montemurro, Michael, additional, Nelson, Garth D., additional, Colgrove, Brian, additional, Gordon, Vallerie, additional, Venook, Alan P., additional, O’Reilly, Eileen M., additional, Meyerhardt, Jeffrey A., additional, Dueck, Amylou C., additional, Basch, Ethan, additional, Chang, George J., additional, and Mamon, Harvey J., additional

Published
2023
Full Text
View/download PDF

34. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4

Author

Leenders, Max, Bhattacharjee, Samsiddhi, Vineis, Paolo, Stevens, Victoria, Bueno-de-Mesquita, H Bas, Shu, Xiao-Ou, Amundadottir, Laufey, Gross, Myron, Tobias, Geoffrey S, Wactawski-Wende, Jean, Arslan, Alan A, Duell, Eric J, Fuchs, Charles S, Gallinger, Steven, Hartge, Patricia, Hoover, Robert N, Holly, Elizabeth A, Jacobs, Eric J, Klein, Alison P, Kooperberg, Charles, LaCroix, Andrea, Li, Donghui, Mandelson, Margaret T, Olson, Sara H, Petersen, Gloria, Risch, Harvey A, Yu, Kai, Wolpin, Brian M, Zheng, Wei, Agalliu, Ilir, Albanes, Demetrius, Boutron-Ruault, Marie-Christine, Bracci, Paige M, Buring, Julie E, Canzian, Federico, Chang, Kenneth, Chanock, Stephen J, Cotterchio, Michelle, Gaziano, J Michael, Giovanucci, Edward L, Goggins, Michael, Hallmans, Göran, Hankinson, Susan E, Hoffman-Bolton, Judith A, Hunter, David J, Hutchinson, Amy, Jacobs, Kevin B, Jenab, Mazda, Khaw, Kay-Tee, Kraft, Peter, Krogh, Vittorio, Kurtz, Robert C, McWilliams, Robert R, Mendelsohn, Julie B, Patel, Alpa V, Rabe, Kari G, Riboli, Elio, Tjønneland, Anne, Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala, Elena, Joanne W, Yu, Herbert, Zeleniuch-Jacquotte, Anne, and Stolzenberg-Solomon, Rachael Z

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Genetics, Pancreatic Cancer, Prevention, Rare Diseases, Aetiology, 2.1 Biological and endogenous factors, Carbon, Case-Control Studies, Cohort Studies, Germ-Line Mutation, Humans, Pancreatic Neoplasms, Polymorphism, Single Nucleotide, United States, Pancreatic cancer, One-carbon metabolism, Polymorphisms, Biomarkers, Public Health and Health Services, Oncology and carcinogenesis
Abstract

PurposeThe evidence of a relation between folate intake and one-carbon metabolism (OCM) with pancreatic cancer (PanCa) is inconsistent. In this study, the association between genes and single-nucleotide polymorphisms (SNPs) related to OCM and PanCa was assessed.MethodsUsing biochemical knowledge of the OCM pathway, we identified thirty-seven genes and 834 SNPs to examine in association with PanCa. Our study included 1,408 cases and 1,463 controls nested within twelve cohorts (PanScan). The ten SNPs and five genes with lowest p values (

Published
2013

37. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer.

Author

Li, Donghui, Duell, Eric J, Yu, Kai, Risch, Harvey A, Olson, Sara H, Kooperberg, Charles, Wolpin, Brian M, Jiao, Li, Dong, Xiaoqun, Wheeler, Bill, Arslan, Alan A, Bueno-de-Mesquita, H Bas, Fuchs, Charles S, Gallinger, Steven, Gross, Myron, Hartge, Patricia, Hoover, Robert N, Holly, Elizabeth A, Jacobs, Eric J, Klein, Alison P, LaCroix, Andrea, Mandelson, Margaret T, Petersen, Gloria, Zheng, Wei, Agalliu, Ilir, Albanes, Demetrius, Boutron-Ruault, Marie-Christine, Bracci, Paige M, Buring, Julie E, Canzian, Federico, Chang, Kenneth, Chanock, Stephen J, Cotterchio, Michelle, Gaziano, J Michael, Giovannucci, Edward L, Goggins, Michael, Hallmans, Göran, Hankinson, Susan E, Hoffman Bolton, Judith A, Hunter, David J, Hutchinson, Amy, Jacobs, Kevin B, Jenab, Mazda, Khaw, Kay-Tee, Kraft, Peter, Krogh, Vittorio, Kurtz, Robert C, McWilliams, Robert R, Mendelsohn, Julie B, Patel, Alpa V, Rabe, Kari G, Riboli, Elio, Shu, Xiao-Ou, Tjønneland, Anne, Tobias, Geoffrey S, Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala, Watters, Joanne, Yu, Herbert, Zeleniuch-Jacquotte, Anne, Amundadottir, Laufey, and Stolzenberg-Solomon, Rachael Z

Subjects
Humans, Pancreatic Neoplasms, Genetic Predisposition to Disease, Case-Control Studies, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Polymorphism, Single Nucleotide, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

Four loci have been associated with pancreatic cancer through genome-wide association studies (GWAS). Pathway-based analysis of GWAS data is a complementary approach to identify groups of genes or biological pathways enriched with disease-associated single-nucleotide polymorphisms (SNPs) whose individual effect sizes may be too small to be detected by standard single-locus methods. We used the adaptive rank truncated product method in a pathway-based analysis of GWAS data from 3851 pancreatic cancer cases and 3934 control participants pooled from 12 cohort studies and 8 case-control studies (PanScan). We compiled 23 biological pathways hypothesized to be relevant to pancreatic cancer and observed a nominal association between pancreatic cancer and five pathways (P < 0.05), i.e. pancreatic development, Helicobacter pylori lacto/neolacto, hedgehog, Th1/Th2 immune response and apoptosis (P = 2.0 × 10(-6), 1.6 × 10(-5), 0.0019, 0.019 and 0.023, respectively). After excluding previously identified genes from the original GWAS in three pathways (NR5A2, ABO and SHH), the pancreatic development pathway remained significant (P = 8.3 × 10(-5)), whereas the others did not. The most significant genes (P < 0.01) in the five pathways were NR5A2, HNF1A, HNF4G and PDX1 for pancreatic development; ABO for H.pylori lacto/neolacto; SHH for hedgehog; TGFBR2 and CCL18 for Th1/Th2 immune response and MAPK8 and BCL2L11 for apoptosis. Our results provide a link between inherited variation in genes important for pancreatic development and cancer and show that pathway-based approaches to analysis of GWAS data can yield important insights into the collective role of genetic risk variants in cancer.

Published
2012

38. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan).

Author

Jacobs, Eric J, Chanock, Stephen J, Fuchs, Charles S, Lacroix, Andrea, McWilliams, Robert R, Steplowski, Emily, Stolzenberg-Solomon, Rachael Z, Arslan, Alan A, Bueno-de-Mesquita, H Bas, Gross, Myron, Helzlsouer, Kathy, Petersen, Gloria, Zheng, Wei, Agalliu, Ilir, Allen, Naomi E, Amundadottir, Laufey, Boutron-Ruault, Marie-Christine, Buring, Julie E, Canzian, Federico, Clipp, Sandra, Dorronsoro, Miren, Gaziano, J Michael, Giovannucci, Edward L, Hankinson, Susan E, Hartge, Patricia, Hoover, Robert N, Hunter, David J, Jacobs, Kevin B, Jenab, Mazda, Kraft, Peter, Kooperberg, Charles, Lynch, Shannon M, Sund, Malin, Mendelsohn, Julie B, Mouw, Tracy, Newton, Christina C, Overvad, Kim, Palli, Domenico, Peeters, Petra HM, Rajkovic, Aleksandar, Shu, Xiao-Ou, Thomas, Gilles, Tobias, Geoffrey S, Trichopoulos, Dimitrios, Virtamo, Jarmo, Wactawski-Wende, Jean, Wolpin, Brian M, Yu, Kai, and Zeleniuch-Jacquotte, Anne

Subjects
Humans, Pancreatic Neoplasms, Genetic Predisposition to Disease, Case-Control Studies, Cohort Studies, Genome-Wide Association Study, Colo-Rectal Cancer, Clinical Research, Rare Diseases, Aging, Cancer, Digestive Diseases, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Prevention, Urologic Diseases, 2.1 Biological and endogenous factors, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

A family history of pancreatic cancer has consistently been associated with increased risk of pancreatic cancer. However, uncertainty remains about the strength of this association. Results from previous studies suggest a family history of select cancers (i.e., ovarian, breast and colorectal) could also be associated, although not as strongly, with increased risk of pancreatic cancer. We examined the association between a family history of 5 types of cancer (pancreas, prostate, ovarian, breast and colorectal) and risk of pancreatic cancer using data from a collaborative nested case-control study conducted by the Pancreatic Cancer Cohort Consortium. Cases and controls were from cohort studies from the United States, Europe and China, and a case-control study from the Mayo Clinic. Analyses of family history of pancreatic cancer included 1,183 cases and 1,205 controls. A family history of pancreatic cancer in a parent, sibling or child was associated with increased risk of pancreatic cancer [multivariate-adjusted odds ratios (ORs) = 1.76, 95% confidence interval (CI) = 1.19-2.61]. A family history of prostate cancer was also associated with increased risk (OR = 1.45, 95% CI = 1.12-1.89). There were no statistically significant associations with a family history of ovarian cancer (OR = 0.82, 95% CI = 0.52-1.31), breast cancer (OR = 1.21, 95% CI = 0.97-1.51) or colorectal cancer (OR = 1.17, 95% CI = 0.93-1.47). Our results confirm a moderate sized association between a family history of pancreatic cancer and risk of pancreatic cancer and also provide evidence for an association with a family history of prostate cancer worth further study.

Published
2010

39. Anthropometric Measures, Body Mass Index, and Pancreatic Cancer: A Pooled Analysis From the Pancreatic Cancer Cohort Consortium (PanScan)

Author

Arslan, Alan A, Helzlsouer, Kathy J, Kooperberg, Charles, Shu, Xiao-Ou, Steplowski, Emily, Bueno-de-Mesquita, H Bas, Fuchs, Charles S, Gross, Myron D, Jacobs, Eric J, Lacroix, Andrea Z, Petersen, Gloria M, Stolzenberg-Solomon, Rachael Z, Zheng, Wei, Albanes, Demetrius, Amundadottir, Laufey, Bamlet, William R, Barricarte, Aurelio, Bingham, Sheila A, Boeing, Heiner, Boutron-Ruault, Marie-Christine, Buring, Julie E, Chanock, Stephen J, Clipp, Sandra, Gaziano, J Michael, Giovannucci, Edward L, Hankinson, Susan E, Hartge, Patricia, Hoover, Robert N, Hunter, David J, Hutchinson, Amy, Jacobs, Kevin B, Kraft, Peter, Lynch, Shannon M, Manjer, Jonas, Manson, Joann E, McTiernan, Anne, McWilliams, Robert R, Mendelsohn, Julie B, Michaud, Dominique S, Palli, Domenico, Rohan, Thomas E, Slimani, Nadia, Thomas, Gilles, Tjønneland, Anne, Tobias, Geoffrey S, Trichopoulos, Dimitrios, Virtamo, Jarmo, Wolpin, Brian M, Yu, Kai, Zeleniuch-Jacquotte, Anne, and Patel, Alpa V

Subjects
Obesity, Cancer, Clinical Research, Nutrition, Prevention, Pancreatic Cancer, Rare Diseases, Digestive Diseases, Adult, Aged, Aged, 80 and over, Body Mass Index, Case-Control Studies, Female, Humans, Logistic Models, Male, Middle Aged, Overweight, Pancreatic Neoplasms, Risk Factors, Sex Distribution, United States, Waist Circumference, Pancreatic Cancer Cohort Consortium, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services
Abstract

BackgroundObesity has been proposed as a risk factor for pancreatic cancer.MethodsPooled data were analyzed from the National Cancer Institute Pancreatic Cancer Cohort Consortium (PanScan) to study the association between prediagnostic anthropometric measures and risk of pancreatic cancer. PanScan applied a nested case-control study design and included 2170 cases and 2209 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression for cohort-specific quartiles of body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), weight, height, waist circumference, and waist to hip ratio as well as conventional BMI categories (underweight, or = 35.0). Models were adjusted for potential confounders.ResultsIn all of the participants, a positive association between increasing BMI and risk of pancreatic cancer was observed (adjusted OR for the highest vs lowest BMI quartile, 1.33; 95% CI, 1.12-1.58; P(trend) < .001). In men, the adjusted OR for pancreatic cancer for the highest vs lowest quartile of BMI was 1.33 (95% CI, 1.04-1.69; P(trend) < .03), and in women it was 1.34 (95% CI, 1.05-1.70; P(trend) = .01). Increased waist to hip ratio was associated with increased risk of pancreatic cancer in women (adjusted OR for the highest vs lowest quartile, 1.87; 95% CI, 1.31-2.69; P(trend) = .003) but less so in men.ConclusionsThese findings provide strong support for a positive association between BMI and pancreatic cancer risk. In addition, centralized fat distribution may increase pancreatic cancer risk, especially in women.

Published
2010

40. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Author

Petersen, Gloria M, Amundadottir, Laufey, Fuchs, Charles S, Kraft, Peter, Stolzenberg-Solomon, Rachael Z, Jacobs, Kevin B, Arslan, Alan A, Bueno-de-Mesquita, H Bas, Gallinger, Steven, Gross, Myron, Helzlsouer, Kathy, Holly, Elizabeth A, Jacobs, Eric J, Klein, Alison P, LaCroix, Andrea, Li, Donghui, Mandelson, Margaret T, Olson, Sara H, Risch, Harvey A, Zheng, Wei, Albanes, Demetrius, Bamlet, William R, Berg, Christine D, Boutron-Ruault, Marie-Christine, Buring, Julie E, Bracci, Paige M, Canzian, Federico, Clipp, Sandra, Cotterchio, Michelle, de Andrade, Mariza, Duell, Eric J, Gaziano, J Michael, Giovannucci, Edward L, Goggins, Michael, Hallmans, Göran, Hankinson, Susan E, Hassan, Manal, Howard, Barbara, Hunter, David J, Hutchinson, Amy, Jenab, Mazda, Kaaks, Rudolf, Kooperberg, Charles, Krogh, Vittorio, Kurtz, Robert C, Lynch, Shannon M, McWilliams, Robert R, Mendelsohn, Julie B, Michaud, Dominique S, Parikh, Hemang, Patel, Alpa V, Peeters, Petra HM, Rajkovic, Aleksandar, Riboli, Elio, Rodriguez, Laudina, Seminara, Daniela, Shu, Xiao-Ou, Thomas, Gilles, Tjønneland, Anne, Tobias, Geoffrey S, Trichopoulos, Dimitrios, Van Den Eeden, Stephen K, Virtamo, Jarmo, Wactawski-Wende, Jean, Wang, Zhaoming, Wolpin, Brian M, Yu, Herbert, Yu, Kai, Zeleniuch-Jacquotte, Anne, Fraumeni, Joseph F, Hoover, Robert N, Hartge, Patricia, and Chanock, Stephen J

Subjects
Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 5, Chromosomes, Human, Pair 13, Humans, Carcinoma, Pancreatic Neoplasms, Genetic Predisposition to Disease, Case-Control Studies, Cohort Studies, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Genetic Loci, Rare Diseases, Cancer, Genetics, Clinical Research, Pancreatic Cancer, Digestive Diseases, Human Genome, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

We conducted a genome-wide association study of pancreatic cancer in 3,851 affected individuals (cases) and 3,934 unaffected controls drawn from 12 prospective cohort studies and 8 case-control studies. Based on a logistic regression model for genotype trend effect that was adjusted for study, age, sex, self-described ancestry and five principal components, we identified eight SNPs that map to three loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Two correlated SNPs, rs9543325 (P = 3.27 x 10(-11), per-allele odds ratio (OR) 1.26, 95% CI 1.18-1.35) and rs9564966 (P = 5.86 x 10(-8), per-allele OR 1.21, 95% CI 1.13-1.30), map to a nongenic region on chromosome 13q22.1. Five SNPs on 1q32.1 map to NR5A2, and the strongest signal was at rs3790844 (P = 2.45 x 10(-10), per-allele OR 0.77, 95% CI 0.71-0.84). A single SNP, rs401681 (P = 3.66 x 10(-7), per-allele OR 1.19, 95% CI 1.11-1.27), maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple cancers. Our study has identified common susceptibility loci for pancreatic cancer that warrant follow-up studies.

Published
2010

41. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer.

Author

Amundadottir, Laufey, Kraft, Peter, Stolzenberg-Solomon, Rachael Z, Fuchs, Charles S, Petersen, Gloria M, Arslan, Alan A, Bueno-de-Mesquita, H Bas, Gross, Myron, Helzlsouer, Kathy, Jacobs, Eric J, LaCroix, Andrea, Zheng, Wei, Albanes, Demetrius, Bamlet, William, Berg, Christine D, Berrino, Franco, Bingham, Sheila, Buring, Julie E, Bracci, Paige M, Canzian, Federico, Clavel-Chapelon, Françoise, Clipp, Sandra, Cotterchio, Michelle, de Andrade, Mariza, Duell, Eric J, Fox, John W, Gallinger, Steven, Gaziano, J Michael, Giovannucci, Edward L, Goggins, Michael, González, Carlos A, Hallmans, Göran, Hankinson, Susan E, Hassan, Manal, Holly, Elizabeth A, Hunter, David J, Hutchinson, Amy, Jackson, Rebecca, Jacobs, Kevin B, Jenab, Mazda, Kaaks, Rudolf, Klein, Alison P, Kooperberg, Charles, Kurtz, Robert C, Li, Donghui, Lynch, Shannon M, Mandelson, Margaret, McWilliams, Robert R, Mendelsohn, Julie B, Michaud, Dominique S, Olson, Sara H, Overvad, Kim, Patel, Alpa V, Peeters, Petra HM, Rajkovic, Aleksandar, Riboli, Elio, Risch, Harvey A, Shu, Xiao-Ou, Thomas, Gilles, Tobias, Geoffrey S, Trichopoulos, Dimitrios, Van Den Eeden, Stephen K, Virtamo, Jarmo, Wactawski-Wende, Jean, Wolpin, Brian M, Yu, Herbert, Yu, Kai, Zeleniuch-Jacquotte, Anne, Chanock, Stephen J, Hartge, Patricia, and Hoover, Robert N

Subjects
Chromosomes, Human, Pair 9, Humans, Pancreatic Neoplasms, Genetic Predisposition to Disease, ABO Blood-Group System, Logistic Models, Odds Ratio, Risk Factors, Case-Control Studies, Cohort Studies, Prospective Studies, Gene Frequency, Genotype, Haplotypes, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Alleles, Introns, United States, Female, Male, Genetic Variation, Genome-Wide Association Study, Prevention, Rare Diseases, Cancer, Genetics, Clinical Research, Pancreatic Cancer, Digestive Diseases, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 x 10(-8); multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.

Published
2009

42. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

Author

Tella, Sri Harsha, primary, Foster, Nathan, additional, Qian, Shi, additional, Nguyen, Tran, additional, Borad, Mitesh J, additional, McWilliams, Robert R, additional, Alberts, Steven R, additional, Wee Ma, Wen, additional, Chakrabarti, Sakti, additional, Fruth, Briant, additional, Wessling, Jaclynn, additional, Hartgers, Mindy, additional, Washburn, Leslie, additional, Fernandez-Zapico, Martin E, additional, Hogenson, Tara L, additional, Pitot, Henry, additional, Jin, Zhaohui, additional, and Mahipal, Amit, additional

Published
2023
Full Text
View/download PDF

43. Data from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Author

Kottschade, Lisa A., primary, Pond, Gregory Russell, primary, Olszanski, Anthony J., primary, Zakharia, Yousef, primary, Domingo-Musibay, Evidio, primary, Hauke, Ralph J., primary, Curti, Brendan D., primary, Schober, Sarah, primary, Milhem, Mohammed M., primary, Block, Matthew Stephen, primary, Hieken, Tina, primary, and McWilliams, Robert R., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Author

Kottschade, Lisa A., primary, Pond, Gregory Russell, primary, Olszanski, Anthony J., primary, Zakharia, Yousef, primary, Domingo-Musibay, Evidio, primary, Hauke, Ralph J., primary, Curti, Brendan D., primary, Schober, Sarah, primary, Milhem, Mohammed M., primary, Block, Matthew Stephen, primary, Hieken, Tina, primary, and McWilliams, Robert R., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Author

Kottschade, Lisa A., primary, Pond, Gregory Russell, primary, Olszanski, Anthony J., primary, Zakharia, Yousef, primary, Domingo-Musibay, Evidio, primary, Hauke, Ralph J., primary, Curti, Brendan D., primary, Schober, Sarah, primary, Milhem, Mohammed M., primary, Block, Matthew Stephen, primary, Hieken, Tina, primary, and McWilliams, Robert R., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma

Author

Yadav, Siddhartha, primary, Kasi, Pashtoon M., primary, Bamlet, William R., primary, Ho, Thanh P., primary, Polley, Eric C., primary, Hu, Chunling, primary, Hart, Steven N., primary, Rabe, Kari G., primary, Boddicker, Nicholas J., primary, Gnanaolivu, Rohan D., primary, Lee, Kun Y., primary, Lindstrom, Tricia H., primary, Petersen, Gloria M., primary, Couch, Fergus J., primary, and McWilliams, Robert R., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results